- Home / RMA Access Center
Ongoing Clinical Trials studies
NOVO Nordisk Trial
Sponsor: Novo Nordisk
Protocol: NN9535-4321 (Phase-3b) (Non-dialysis)
A randomized Double-blind, Event – driven, Placebo controlled, multicenter study of the Effect of Semaglutide versus placebo on the progression of renal impairment in subjects with type 2 diabetes and chronic kidney disease. Open for Enrollment:
INSPIRE-CKD
Sponsor: Idorsia
Protocol: ID-080A305 (Phase-3) (Non-dialysis)
Multi-center, Double-blinded, randomized study with aprocitentan in subjects with uncontrolled blood pressure and chronic kidney disease stage 3 or 4.
Akebia Trial
Sponsor: Akebia Therapeutics
Protocol: AKB-6548-CI (Phase-3) (Non-dialysis)
A Randomized, Open-label, Active-controlled study evaluating the Efficacy and Safety of Oral Vadadustat for the correction of Anemia in subjects with non -dialysis and dialysis dependent Chronic Kidney Disease.
CARA Trail
Sponsor: Cara Therapeutics
Protocol: CR845-CLIN3101, 3102 and 3103 (Phase 3) (Dialysis)
AN OPEN-LABEL, MULTICENTER, EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY OF INTRAVENOUS CR845 IN HEMODIALYSIS PATIENTS WITH CHRONIC KIDNEY DISEASE-ASSOCIATED PRURITUS.Contact research team member

Dr Jayan Kumar
(kumar@renalmed.com) Principal Investigator Renal Medicine Associates 3821 Masthead NE Albuquerque NM 87109
Phone: 505-998-7400

Angela Contreras
(angela.c@renalmed.com) Clinical Research Coordinator Renal Medicine Associates 3821 Masthead NE Albuquerque NM 87109
Phone: 505-998-7400

Hema Shah
(hema.s@renalmed.com Senior Clinical Research Coordinator Renal Medicine Associates 3821 Masthead NE Albuquerque NM 87109
Phone: 505-998-7460 or 505-998-7400

Marlene Carbajal-Villena
(marlene.c@renalmed.com) Clinical Research Coordinator Renal Medicine Associates 3821 Masthead NE Albuquerque NM 87109
Phone: 505-998-7460 or 505-998-7400
- Choosing a selection results in a full page refresh.
- Press the space key then arrow keys to make a selection.